서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 35 of 35

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-01
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
DOI
2005-04
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
DOI
2006-04
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
DOI
2006-06
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer
DOI
2006-07
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy
DOI
2006-11
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients
DOI
2007-05
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
DOI
2008-03
High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer
DOI
2008-06
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
DOI
2008-07
Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment
DOI
2009-08
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
DOI
2010-03
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
DOI
2011-01
High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
DOI
2011-10
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
DOI
2012-01
Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer
DOI
2012-03
Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody
DOI
2013-04
Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy
DOI
2013-05
Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing
DOI
2013-12
Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines
DOI
2014-07
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HIVI30181A, in Patients with Advanced Solid Cancer
DOI
2014-08
Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from Ga-68-RGD PET/CT and F-18-FDG PET/CT
DOI
2015-08
Phase I/II study of weekly Oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer
DOI
2015-09
Radioactive iodine therapy did not significantly increase the incidence and recurrence of subsequent breast cancer
DOI
2016-07
Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel H-1-magnetic resonance spectroscopy and F-18-fluorodeoxyglucose positron emission tomography
DOI
2018-04
Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors
DOI
2019-01
Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients
DOI
2019-10
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
DOI
2019-12
Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response

Jeon, Seung Hyuck; Chie, Eui Kyu; Kim, Yi-Jun; Lee, Kyung-Hun; Lee, Hyun-Seob; Kim, Min Jung; Im, Seock-Ah; Kim, Jong-Il; Kim, Tae-You

International Journal of Radiation Biology, Vol.95 No.12, pp.1640-1647

DOI
2020-06
Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
DOI
2020-10
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer
DOI
2021-01
Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy
DOI
2021-08
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
DOI
2022-04
Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis
DOI
2022-10
Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
DOI
2022-11
Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer
DOI
1